TechFlow, November 11 — YZi Labs today announced an investment in regenerative medicine company Renewal Bio, marking YZi Labs' first biotechnology investment since expanding its investment scope in early 2025. Renewal Bio focuses on using its proprietary Stembroid™ platform to generate human cells and tissues with fully matched DNA from a patient’s own cells, aiming to address the global organ shortage crisis.
Over 150,000 organ transplants are performed globally each year, yet less than 10% of demand is met. Renewal Bio reprograms ordinary skin or blood cells into stem cells by simulating the early human developmental environment, generating multiple functional cell types including hematopoietic, liver, heart, and pancreatic cells.
The company was founded in 2022 by Professor Jacob Hanna of the Weizmann Institute of Science and two doctoral students from his lab, Vladislav Krupalnik and Ohad Gafni. This funding round will accelerate the preclinical development of Stembroid-derived hematopoietic stem cells for treating leukemia and immune disorders, and support expansion of laboratory infrastructure.
